- Rating
- 2
- Confidence
- 3
- Informativeness
- 2
- Presentation
- 2
- Soundness
- 2
Read review
Paper summary
This paper proposes MolGAN, a teacher-free adversarial model for 3D molecular generation using a small number of external refinement passes. The generator adapts the Hierarchical Reasoning Model with recurrent high- and low-level latent states to iteratively refine atom types and coordinates. Training combines a relativistic energy-based adversarial objective, persistent carries, stochastic refinement with truncated gradients, VISReg, and a learned PAD atom for varying molecule size. On QM9 and GEOM-DRUG, MolGAN reports strong validity and stability with four external passes, and its discriminator is further used for candidate selection and trajectory-based early stopping. Lower-energy candidate selection improves several reported molecular-property scores. Overall, the results suggest that adversarial hierarchical refinement can generate valid molecules with short external trajectories. However, the claimed quality–efficiency advantage is not yet established once internal recurrent computation and the substantially lower QM9 diversity are considered.
Critical strengths
-
A promising teacher-free approach to short-trajectory molecular generation. The paper offers an alternative to diffusion distillation by combining hierarchical recurrent refinement with adversarial training. Joint atom/coordinate prediction and the learned PAD category provide a flexible mechanism for molecule generation without requiring a pretrained diffusion teacher.
-
Encouraging validity and stability across two datasets. At four external passes, MolGAN reports competitive stability and validity on QM9 and strong atom stability and validity on GEOM-DRUG. The discriminator-based candidate-selection experiment is also interesting, as larger candidate pools improve QED, normalized SA, and Lipinski scores.
Critical weaknesses
-
The quality–efficiency claim lacks comparable compute accounting and is weakened by low diversity. A MolGAN “NFE” contains multiple internal HRM module evaluations, each involving Transformer computation. Therefore, external pass count alone is not a comparable measure of computational cost. The paper does not report the relevant recurrence counts, model size, latency, throughput, or memory, so Figure 2 demonstrates efficiency in terms of external trajectory length rather than actual computation. The QM9 diversity result is also concerning: four-pass MolGAN achieves only 34.71% valid-and-unique samples versus 72.70% for four-step FlashMol, despite similar validity. This substantially reduces its practical value for virtual screening and molecular exploration. A stronger efficiency comparison should therefore measure the cost of obtaining a fixed number of valid unique molecules.
-
The proposed mechanisms and generated 3D distribution are insufficiently validated. MolGAN combines hierarchical recurrence, persistent carries, truncated gradients, coordinate rescaling, PAD atoms, and VISReg, but quantitative ablations isolating these components are largely absent. In particular, there is no comparison against a conventional recurrent Transformer under matched parameter and compute budgets. The molecular evaluation is also incomplete. GEOM-DRUG lacks uniqueness, novelty, and coverage metrics, while the 3D evaluation does not directly examine bond-angle or torsion distributions, steric clashes, or conformational energies. Candidate selection improves several scalar property metrics but also increases the PAINS rate, and its effects on diversity and 3D quality are not reported. Thus, it remains unclear whether selection broadly improves molecular quality or concentrates generation into a narrower region of chemical space.
Questions for authors
-
Compute and efficiency. What are the values of the internal recurrence parameters, Transformer depth, and generator parameter count? Can the authors report latency and throughput against the main few-step baseline on identical hardware, including the cost of generating a fixed number of valid unique molecules?
-
Diversity and evaluation protocol. How are uniqueness and (V\times U) computed, including sample count, molecular representation, and stereochemical conventions? Were all baselines evaluated under the same protocol? Please also report uniqueness and novelty on GEOM-DRUG and discuss the low QM9 diversity.
-
Contribution of hierarchical computation. How does MolGAN compare with a conventional recurrent Transformer under matched parameters and computation? Please provide controlled ablations for persistent carries, truncated gradients, coordinate scaling, and VISReg, ideally with variation across independent runs.
-
Reproducibility and discriminator state. Please specify the main training hyperparameters, coordinate scaling, PAD sampling, dataset splits, and molecule-reconstruction procedure. How are generator and energy-model carries initialized and reused at evaluation time? In particular, are VISReg views and candidate energies evaluated under identical carry states?
-
Test-time selection and early stopping. Can the authors provide matched random-selection results for each candidate-pool size, with uncertainty, uniqueness, molecular size, and geometric-quality metrics? How should the increased PAINS rate be interpreted? For early stopping, what is the net computational saving after including discriminator evaluations and the extra pass required to detect an energy increase?